Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 15;11(24):7457.
doi: 10.3390/jcm11247457.

A Review of Ophthalmic Complications in Inflammatory Bowel Diseases

Affiliations
Review

A Review of Ophthalmic Complications in Inflammatory Bowel Diseases

Wiktoria Pytrus et al. J Clin Med. .

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-mediated conditions caused by various polygenic and environmental factors. Clinical manifestations of IBD primarily occur in the gastrointestinal tract, but many patients are affected by extraintestinal complications, including eye diseases. Ocular disorders are the third most common extraintestinal manifestation (EIM), following musculoskeletal and mucocutaneous involvement. Episcleritis, frequently occurring in IBD patients, may be associated with exacerbation of the intestinal disease. Uveitis does not correlate with IBD activity but may be related to the presence of other EIMs, particularly erythema nodosum and peripheral arthritis. Early detection and specific therapy of ocular manifestations of IBD are fundamental to avoiding sight-threatening complications. Therefore, ophthalmic evaluation should be performed in all IBD patients. Systemic corticosteroids or immunosuppressants may be inevitable in severe cases to control ocular inflammation. Persistent and relapsing conditions usually respond well to TNF-α-inhibitors. Interdisciplinary cooperation between gastroenterologists and ophthalmologists is fundamental in initiating the appropriate treatment for patients.

Keywords: extraintestinal manifestation; inflammatory bowel disease; ocular involvement.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Scleritis.
Figure 2
Figure 2
Translucent sclera with visible blue-black uveal tissue.
Figure 3
Figure 3
Scleromalacia perforans (treated with scleral allo-graft).
Figure 4
Figure 4
Peripheral ulcerative keratitis.

References

    1. Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. J. Clin. Med. 2022;11:5267. doi: 10.3390/jcm11185267. - DOI - PMC - PubMed
    1. M’Koma A.E. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina. 2022;58:567. doi: 10.3390/medicina58050567. - DOI - PMC - PubMed
    1. Elhag D.A., Kumar M., Saadaoui M., Akobeng A.K., Al-Mudahka F., Elawad M., Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int. J. Mol. Sci. 2022;23:6966. doi: 10.3390/ijms23136966. - DOI - PMC - PubMed
    1. Younis N., Zarif R., Mahfouz R. Inflammatory bowel disease: Between genetics and microbiota. Mol. Biol. Rep. 2020;47:3053–3063. doi: 10.1007/s11033-020-05318-5. - DOI - PubMed
    1. Ni J., Wu G.D., Albenberg L., Tomov V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017;14:573–584. doi: 10.1038/nrgastro.2017.88. - DOI - PMC - PubMed

LinkOut - more resources